Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs)Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6...